BACKGROUND Ovarian hyperstimulation syndrome (OHSS) is the most serious and potentially life-threatening iatrogenic complication associated with ovarian stimulation during Assisted Reproductive Technology (ART) protocols. OHSS typically is a result of ovarian expression of vascular endothelial growth factor (VEGF) which increases vascular permeability. OBJECTIVE Comparison of albumin and cabe...

Ovarian hyperstimulation syndrome (OHSS) is rare but most serious complication of ovarian stimulation. Symptoms are mainly related to increased capillary permeability leading to extravasation of fluid into extravascular compartment. Disease pathophysiology is linked to hCG (human chorionic gonadotropin) which acts through angiogenic molecule vascular endothelial growth factor (VEGF). There is r...

Ovarian hyperstimulation syndrome (OHSS) remains a major complication of IVF. Triggering ovulation with human chorionic gonadotrophin (HCG) (as a surrogate to LH) is a major factor in the initiation of OHSS. The pathological process usually intensifies if pregnancy is achieved, as the rising endogenous HCG overstimulates the corpora lutea. Decreasing HCG trigger dose does not prevent OHSS. Gona...

Type 2 receptors for vascular endothelial growth factor are believed to be involved in the pathophysiology of ovarian hyperstimulation syndrome (OHSS). The objective of this study was to examine the preventive effects of cabergoline on OHSS and its complications. The study is a non randomized clinical trial conducted in 2006-2008 on 75 patients, which were at risk of OHSS and underwent assisted...

STUDY QUESTION Is severe early ovarian hyperstimulation syndrome (OHSS) completely prevented with the GnRH agonist trigger and 1500 IU hCG luteal rescue protocol? SUMMARY ANSWER Severe early OHSS can occur even after the GnRH agonist trigger and 1500 IU hCG luteal rescue protocol. WHAT IS KNOWN ALREADY Prior studies including over 200 women who received the GnRH agonist trigger and 1500 hCG...

Background: Coasting is the most common method used in the prevention of ovarian hyperstimulation syndrome (OHSS) acting through vascular endothelial growth factor (VEGF) reduction. However, the pregnancy rate is reported to fall with coasting when it takes more than three days. Recently lowdose cabergoline, a selective D2 dopamine receptor agonist has been proven to selectively reduce vascular...

BACKGROUND The beneficial role of cabergoline as a prophylactic agent to prevent ovarian hyper stimulation syndrome (OHSS) among high-risk patients has been demonstrated in previous studies. But data for its role as a treatment for established severe OHSS is still limited. We represent the treatment results of high dose oral cabergoline in management of six patients after the syndrome is establ...

OBJECTIVE To review the available knowledge on the use of GnRH agonist for ovulation triggering as a means to prevent ovarian hyperstimulation syndrome (OHSS). DESIGN(S) Review of pertinent English language studies published over the past 15 years. RESULT(S) The available literature suggests that while GnRH agonist effectively induces final oocyte maturation and ovulation, it also completel...

Ovarian hyperstimulation syndrome (OHSS) is a complication that occurs in the luteal phase of an induced hormonal cycle. In most cases, the symptoms are self-limited, and spontaneous regression occurs [1]. Mild manifestations of OHSS include transient lower abdominal discomfort, nausea, vomiting, diarrhea, and abdominal distension. Life-threatening OHSS can progress to adult respiratory distres...

BACKGROUND A bolus dose of GnRH agonist can substitute for hCG as a trigger for the resumption of meiosis in ovarian stimulation with GnRH antagonists, which has been suggested to reduce the risk of ovarian hyperstimulation syndrome (OHSS). As the efficacy of this measure in fresh embryo transfer (ET) cycles is unclear, we evaluated a new clinical concept of GnRH-agonist triggering. METHODS I...